ANP32A regulates histone H3 acetylation and promotes leukemogenesis.

Leukemia
Xuejing YangZan Huang

Abstract

Deregulation of key regulators of histone modification is important in the initiation and progression of human leukemia. Acidic leucine-rich nuclear phosphoprotein-32A (ANP32A) participates in histone acetylation and its role in acute myeloid leukemia remains unclear. Here we observed significant upregulation of ANP32A in primary AML cells, which was essential for AML cell proliferation, survival, and colony formation. Integrative analysis of the genome-wide histone H3 acetylation and gene expression demonstrated that ANP32A deficiency reduced histone H3 acetylation, in accordance with changes in gene expression. Notably, significant histone H3 acetylation enrichment was associated with mRNA changes in lipid-related genes, including APOC1, PCSK9, P2RX1, and LPPR3. Indeed, over-expression of APOC1 partially compensated the proliferation-defect phenotype in ANP32A deficient AML cells while APOC1 knockdown alone mimicked the effect of ANP32A deficiency. Collectively, our data indicate that ANP32A is a novel regulator of histone H3 acetylation and promotes leukemogenesis.

References

Apr 29, 1998·Annual Review of Physiology·E B Thompson
Jul 10, 1999·The Journal of Biological Chemistry·J R BrodyG R Pasternack
Feb 7, 2002·The Journal of Biological Chemistry·Sang-beom SeoDebabrata Chakravarti
Dec 26, 2003·The American Journal of Pathology·Jonathan R BrodyGary R Pasternack
Apr 3, 2004·Molecular and Cellular Biology·Puneet OpalHuda Y Zoghbi
Apr 16, 2004·The New England Journal of Medicine·Peter J M ValkRuud Delwel
Apr 22, 2004·The Journal of Biological Chemistry·Robert SchneiderTony Kouzarides
Jul 11, 2006·International Journal of Cancer. Journal International Du Cancer·Véronique OuelletAnne-Marie Mes-Masson
Oct 2, 2007·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Jonathan R BrodyCharles J Yeo
Sep 19, 2008·Genome Biology·Yong ZhangX Shirley Liu
Jan 6, 2009·The Journal of Biological Chemistry·Wei PanXuejun Jiang
Mar 6, 2009·Genome Biology·Ben LangmeadSteven L Salzberg
Jul 22, 2009·Molecular and Cellular Biology·Zan HuangJohn D Crispino
Aug 5, 2010·Clinical & Experimental Metastasis·Bu-Dong ZhuChun-Ping Cui
Sep 14, 2011·Methods in Molecular Biology·Henriette O'GeenPeggy J Farnham
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Aug 27, 2014·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Patrick T ReillyLishun Wang
Jun 15, 2015·Experimental Hematology·Tim SauerCarsten Müller-Tidow
Jan 26, 2016·Oncogenesis·S Beloribi-DjefafliaF Guillaumond
Sep 28, 2016·World Journal of Gastroenterology : WJG·Ferenc SiposGyörgyi Műzes
Dec 3, 2016·Nucleic Acids Research·UNKNOWN BIG Data Center Members

❮ Previous
Next ❯

Citations

Oct 2, 2019·Cancer Medicine·Liwen RenGuanhua Du
Dec 21, 2019·Journal of Cellular Physiology·Raffaella PippaAntonio Giordano
Jun 27, 2019·Current Medicinal Chemistry·Maria Hernandez-ValladaresAstrid Guldbrandsen
Mar 10, 2021·In Vitro Cellular & Developmental Biology. Animal·X LiL Lian
May 23, 2021·Andrologia·Yun PengHaitao Wang

❮ Previous
Next ❯

Methods Mentioned

BETA
histone acetylation
acetylation
PCR
immunoprecipitation
ChIP-seq
ChIP
ChIPseq
xenograft

Software Mentioned

DiffReps
MACS
Limma
Bowtie2

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.